Merck, Bristol, Gilead Are In Discussions For Combo HIV Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck, Bristol-Myers Squibb, and Gilead are in discussion to develop a co-packaged version of three different AIDS drugs for use in the developing world
You may also be interested in...
Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
The joint venture is expected to use a new brand name for the fixed-dose combination of Sustiva and Truvada. Bristol and Gilead will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products.”
Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
The joint venture is expected to use a new brand name for the fixed-dose combination of Sustiva and Truvada. Bristol and Gilead will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products.”
FDA Combo HIV Therapy Review Process May Delay Availability, Rep. Waxman Says
The agency's new regulatory framework for expedited review of fixed-dose combination antiretroviral drugs is "highly misleading," Rep. Waxman says in letter to HHS Secretary Thompson. Waxman believes the proposal will delay purchase of generic combo therapies used outside the U.S.